John Brady
Question:31. Deputy John Brady asked the Minister for Health the number of drugs where, following the National Centre for Pharmacoeconomics, NCPE, assessment of the manufacturer's economic dossier on the cost-effectiveness of a drug, including details on all relevant costs and relevant cost offsets including hospitalisation, disease management costs, intravenous antibiotics, adverse events and any additional costs arising in patients not taking a drug, the NCPE found a drug not to be cost-effective; if he will provide this information for each of the past five years with a breakdown of whether additional price reductions were successfully negotiated and agreed upon; and if he will make a statement on the matter. [37860/16]
View answer